跳至主要内容
临床试验/NCT06409416
NCT06409416尚未招募不适用

Identification of Molecular Mechanisms Which Drive Tumor Cell Plasticity and Aggressiveness in Human Non-small Cell Lung Cancer

Casa Sollievo della Sofferenza IRCCS0 个研究点目标入组 20 人开始时间: 2024年7月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
20
主要终点
TCP-biomarkers screening in a prospective cohort of lung cancer patients

研究概览

简要总结

Tumor cell plasticity (TCP) is a conubium of processes which lead to re-activation of developmental programs correlating with epithelial-to-mesenchymal transition, and ultimately leading to acquisition of stem cell properties and transdifferentiation potential. Little is known about the molecular mechanisms governing TCP in lung adenocarcinoma (LUAD), i.e. the most frequent lung cancer subtype. The investigators recently identified prognostic 7-miRNAs/10-mRNAs signatures which accurately identified aggressive LUAD among patients with early-stage disease (Stage I). Furthermore, the investigators showed that such tumors show TCP features i.e. mesenchymal and stem-cell traits, high-metastatic potential. Here, the investigators aim to explore by RNAseq and by immunophenotyping at a single-cell level (scRNAseq/AbSeq), the molecular features of aggressive LUAD to unveil the mechanisms triggering TCP. The investigators predict thier results will be relevant for the development of more effective therapeutic protocols for management of aggressive LUAD.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • patients diagnosed with lung adenocarcinoma
  • treatment naive
  • undergoing primary surgery

排除标准

  • patients with a previous history of cancer
  • previously treated by chemio/immuno/radio-therapy

结局指标

主要结局

TCP-biomarkers screening in a prospective cohort of lung cancer patients

时间窗: 36 months

The investigators will: i) deconvolute the tumor epithelial cell heterogeneity of lung adenocarcinoma (LUAD) by coupling immunophenotype screening and single-cell RNAseq profiling of human LUAD samples; ii) identify subsets of LUAD cells with "active" tumor cell plasticity (TCP) using both our miRNA/RNA prognostic signatures, the C1-LUAD geneset (N=330), and previously identified signatures of lung cells high-cell plasticity (HCP) state; iii) explore the molecular features of TCP cell subsets by gene-network rewiring, pathway reconstruction analysis, and functional validation experiments of molecular "HUBs" controlling TCP pathways. Biomarkers of TCP will be also prioritized among TCP-hallmark genes and validated by immunohistochemistry (IHC/FACS) in human LUAD.

次要结局

未报告次要终点

研究者

发起方
Casa Sollievo della Sofferenza IRCCS
申办方类型
Other
责任方
Principal Investigator
主要研究者

Fabrizio Bianchi

Head, cancer Biomarkers Unit

Casa Sollievo della Sofferenza IRCCS

相似试验